Arterial hypertension (HTN) represents the major cardiovascular risk factor and still represents a global health issue. In the last two years, three international societies published the new guidelines for the treatment of HTN (European Society of Cardiology, 2025; European Society of Hypertension, 2023; and American College of Cardiology in collaboration with American Heart Association, 2025), with many novelties which have been the object of many discussions among experts. The increased stress on screening programs, the new lower targets to reach by medical treatment, and the new strategies for resistant hypertension have raised some doubt on the feasibility of these recommendations in clinical practice. In this perspective document, the authors highlight and discuss the novelties and potential pros and cons of the new international recommendations for the treatment of arterial HTN. © 2025 by the authors.
Pastore, M.C., Carmona De Azevedo Bellagamba, C., Liga, R., Stefanini, A., Durante, M., D'Ascenzi, F., et al. (2025). How the Latest Guidelines Are Changing the Diagnostic and Therapeutic Landscape of Arterial Hypertension. JOURNAL OF CLINICAL MEDICINE, 14(21) [10.3390/jcm14217694].
How the Latest Guidelines Are Changing the Diagnostic and Therapeutic Landscape of Arterial Hypertension
Pastore, Maria Concetta
;Carmona De Azevedo Bellagamba, Clarissa;Durante, Miriam;D'Ascenzi, Flavio;Cameli, Matteo
2025-01-01
Abstract
Arterial hypertension (HTN) represents the major cardiovascular risk factor and still represents a global health issue. In the last two years, three international societies published the new guidelines for the treatment of HTN (European Society of Cardiology, 2025; European Society of Hypertension, 2023; and American College of Cardiology in collaboration with American Heart Association, 2025), with many novelties which have been the object of many discussions among experts. The increased stress on screening programs, the new lower targets to reach by medical treatment, and the new strategies for resistant hypertension have raised some doubt on the feasibility of these recommendations in clinical practice. In this perspective document, the authors highlight and discuss the novelties and potential pros and cons of the new international recommendations for the treatment of arterial HTN. © 2025 by the authors.| File | Dimensione | Formato | |
|---|---|---|---|
|
jcm-14-07694-v3.pdf
accesso aperto
Descrizione: Note
Tipologia:
PDF editoriale
Licenza:
Creative commons
Dimensione
236.59 kB
Formato
Adobe PDF
|
236.59 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1302435
